Innoviva, Inc. (INVA)

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Address

1350 OLD BAYSHORE HIGHWAY
BURLINGAME, CA 94010

Founded

1996

Number of Employees

112

Website

http://www.inva.com

Buyback

Buyback Data 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
$ Amount Purchased
($ in 000s)		 - $25,638 $78,086 $97,510 - - - - $8,500 $75,887 $14,925 $50,091
Average Price - $9.58 $10.84 $13.12 - - - - $13.13 $12.29 $15.12 $11.97
# Shares Purchased - 2,676,236 7,201,448 7,430,106 - - - - 647,394 6,173,565 986,928 4,185,946
Buyback Performance 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Average
Total Return to Date - 98.3% 75.2% 44.8% - - - - 44.7% 54.6% 25.6% 58.8%
S&P 500 Return to Date - 173.0% 168.6% 129.7% - - - - 37.3% 31.3% 7.4% 91.2%
Excess Total Return - -74.6% -93.4% -84.9% - - - - 7.4% 23.2% 18.2% -32.4%
Quartile Rank
Percentile Rank - 59% 54% 54% - - - - 77% 86% 83% 74%
Buyback returns calculated using weighted average buyback price over the last 10 years and comparing to current day stock price value. S&P 500 used as benchmark for excess return.

Insider Transactions

Filters

Keyboard Shortcuts: Show (a) | Close (Esc)

People also followed
IDEAYA Biosciences, Inc.
ANAPTYSBIO, INC
INSMED Inc
WINNINGHAM RICK E

Innoviva, Inc.